AC
SAGE

AXQ Capital’s Sage Therapeutics SAGE Stock Holding History

AXQ Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,152
Closed -$184K – 796
2025
Q2 		$184K Buy
+20,152
New +$148K 0.06% 473
2024
Q2 		– Sell
-10,570
Closed -$198K – 696
2024
Q1 		$198K Buy
+10,570
New +$244K 0.05% 519
2023
Q2 		– Sell
-14,412
Closed -$605K – 524
2023
Q1 		$605K Buy
+14,412
New +$620K 0.24% 132

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AXQ Capital's SAGE Position: Q3 2025 in Review

AXQ Capital sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 20,152 shares — an estimated $184K sold.

AXQ Capital first reported a position in SAGE in Q1 2023 and held it in 3 quarters. The position peaked at $605K in Q1 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • AXQ Capital reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AXQ Capital sold 20,152 Sage Therapeutics shares in Q3 2025, an estimated $184K.
  • AXQ Capital first reported a position in Sage Therapeutics in Q1 2023 and held it in 3 quarters.
  • AXQ Capital's Sage Therapeutics position peaked at $605K in Q1 2023.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on AXQ Capital's 13F filing for Q3 2025, filed 10 Nov 2025.